Patent Acquisition, Term and Exclusivity
First written in FY2023. 3 of 5 entries say "Mitigated", first in FY2024-Q3. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MitigatedAnnual report
「A use patent for treating acute kidney injury with TMS-008 was granted in the United States in November 2024, following grants in Japan in October 2023 and China in December 2023.」
The TMS-008 acute kidney injury use patent was granted in the United States in November 2024 after grants in Japan and China in 2023. - FY2025-H1RestatedAnnual report
「A patent relating to the SMTP compounds, “Drug for treating or preventing cerebral hemorrhage and method of treating or preventing cerebral hemorrhage using the drug,” was granted in Japan in May 2024. It was granted in the United States in December 2023.」
The Company reiterated the grant of the relevant Japanese patent and stated that the U.S. patent was granted in December 2023. - FY2025-Q1MitigatedAnnual report
「A patent relating to the SMTP compounds, “Drug for treating or preventing cerebral hemorrhage and method of treating or preventing cerebral hemorrhage using the drug,” was granted in Japan in May 2024. It was granted in the United States in May 2021.」
The cerebral hemorrhage treatment and prevention patent relating to the SMTP compounds was granted in Japan in May 2024, following the U.S. grant. - FY2024-Q3MitigatedAnnual report
「A patent relating to this development was granted in Japan in September 2023 and in China in December, and is scheduled to undergo examination in major countries in due course.」
Patents relating to TMS-008 development were granted in Japan and China, advancing protection of the intellectual property. - FY2023First statedAnnual report
「For TMS-007, certain patents transferred to Biogen are expected to remain valid through 2030, while patents under application, if granted, are expected to expire in 2042. If applicable patent-term extensions are not granted, or if patent applications transferred to Biogen do not mature into enforceable rights and cannot secure TMS-007’s exclusivity, the amount of milestone and royalty income paid by Biogen could be adversely affected.」
The Company highlights risks related to obtaining and maintaining patents, patent terms and exclusivity, and states expected expiry years for patents covering TMS-007, TMS-008 and TMS-009.